| First Author | Nie H | Year | 2025 |
| Journal | Cancer Res | Volume | 85 |
| Issue | 18 | Pages | 3471-3489 |
| PubMed ID | 40658600 | Mgi Jnum | J:371970 |
| Mgi Id | MGI:8244904 | Doi | 10.1158/0008-5472.CAN-25-0654 |
| Citation | Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res 85(18):3471-3489 |
| abstractText | Subunits of the SWI/SNF chromatin remodeling complex are altered in approximately 20% of human cancers. Exemplifying the alterations is the ARID1A mutation that occurs in approximately 50% of ovarian clear-cell carcinoma (OCCC), a disease with limited therapeutic options. In this study, we showed that ARID1A mutations create a dependence on alanine by regulating alanine transporters to increase intracellular alanine levels. ARID1A directly repressed the alanine importer SLC38A2 and simultaneously promoted the alanine exporter SLC7A8. ARID1A inactivation increased alanine utilization predominantly in protein synthesis and passively through the tricarboxylic acid cycle. Indeed, ARID1A-mutant OCCCs were hypersensitive to the inhibition of SLC38A2. In addition, SLC38A2 inhibition enhanced chimeric antigen receptor T-cell assault in vitro and synergized with immune checkpoint blockade using an anti-PD-L1 antibody in a genetically engineered mouse model of OCCC driven by conditional Arid1a inactivation in a CD8+ T-cell-dependent manner. These findings suggest that targeting alanine transport alone or in combination with immunotherapy may represent an effective therapeutic strategy for ARID1A-mutant cancers. SIGNIFICANCE: ARID1A mutations regulate expression of alanine transporters to control alanine distribution between cancer cells and the associated tumor microenvironment, which may be exploited therapeutically alone or in combination with immunotherapy. |
